Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future

Experts discuss the recommended guidelines for managing operable, advanced, or metastatic renal cell carcinoma, including the latest data on emerging therapies and adverse event management. Download the slidsesets from a live CME/CE/CPE-certified satellite symposium presented in Chicago at ASCO 2023 and read an expert commentary.

Share

Program Content

Activities

Management of Nonmetastatic RCC
Management of Nonmetastatic RCC at Initial Diagnosis
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

First-line Therapies in Advanced or Metastatic RCC
First-line Therapies in Advanced or Metastatic RCC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

Post Immune Checkpoint Inhibitor Therapy for RCC
Post Immune Checkpoint Inhibitor Therapy for RCC: Second-line Therapy and Beyond
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

Activities

Keeping Pace in RCC
Keeping Pace With Rapid Changes in the Management of RCC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 19, 2023

Faculty

cover img faculity

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

cover img faculity

Stephanie A. Berg, DO

Instructor of Medicine
Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network.

Supporters

Supported by educational grants from AVEO Pharmaceuticals, Inc. (“AVEO Oncology”) and Eisai. Supported by a medical education grant from Exelixis, Inc.

AVEO Pharmaceuticals, Inc.

Eisai

Exelixis, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

In partnership with Clinical Care Options, LLC.